UMIN試験ID | UMIN000039881 |
---|---|
受付番号 | R000045480 |
科学的試験名 | 転移性尿路上皮癌におけるフレイルが予後に与える影響(FRA-mUC study) |
一般公開日(本登録希望日) | 2020/03/20 |
最終更新日 | 2023/03/21 09:55:18 |
日本語
転移性尿路上皮癌におけるフレイルが予後に与える影響(FRA-mUC study)
英語
Effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRAmUC study)
日本語
転移性尿路上皮癌におけるフレイルが予後に与える影響(FRA-mUC study)
英語
Effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRA-mUC study)
日本語
転移性尿路上皮癌におけるフレイルが予後に与える影響(FRA-mUC study)
英語
An observational study of the effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRA-mUC study)
日本語
転移性尿路上皮癌におけるフレイルが予後に与える影響(FRAM-UC study)
英語
An observational study of the effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRA-mUC study)
日本/Japan |
日本語
metastatic urothelial carcinoma
英語
metastatic urothelial carcinoma
泌尿器科学/Urology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
To investigate the association between the frailty and prognosis in patients with metastatic urothelial carcinoma
英語
To investigate the association between the frailty and prognosis in patients with metastatic urothelial carcinoma
安全性・有効性/Safety,Efficacy
日本語
英語
日本語
The primary outcome was the effect of frailty on tumor response in patients with metastatic urothelial carcinoma
英語
The primary outcome was the effect of frailty on progression-free survival in patients with metastatic urothelial carcinoma
日本語
Secondary outcomes included safety, progression-free survival, and overall survival.
英語
Secondary outcomes included safety, progression-free survival, and overall survival.
観察/Observational
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
20 | 歳/years-old | 以上/<= |
100 | 歳/years-old | 未満/> |
男/Male
日本語
Patients with metastatic urothelial carcinoma who were 1) treated with standard of care,2) evaluated with frailty
英語
Patients with metastatic urothelial carcinoma who were 1) treated with standard of care,2) evaluated with frailty
日本語
Patients with metastatic urothelial carcinoma who were not treated with standard of care or no frailty evaluation.
英語
Patients with metastatic urothelial carcinoma who were not treated with standard of care or no frailty evaluation.
200
日本語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
英語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou
英語
Hirosaki
0172395091
shingorilla2@gmail.com
日本語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
英語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou
英語
Hirosaki
0172395091
shingorilla2@gmail.com
日本語
弘前大学
英語
Hirosaki University School of Medicine
日本語
日本語
日本語
英語
日本語
弘前大学
英語
Hirosaki University School of Medicine
日本語
日本語
その他の国の官庁/Government offices of other countries
日本語
日本
英語
日本語
英語
日本語
英語
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
5 Zaifu-chou
英語
Hirosaki
+81172395091
rinri@hirosaki-u.ac.jp
いいえ/NO
日本語
英語
日本語
英語
2020 | 年 | 03 | 月 | 20 | 日 |
未公表/Unpublished
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
限定募集中/Enrolling by invitation
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 06 | 日 |
2025 | 年 | 03 | 月 | 31 | 日 |
日本語
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-UC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
In the PC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments (FRAPC study), the effect of frailty on safety and oncological outcomes 2) between the radical prostatectomy and radiation therapy in patients with localized prostate cancer (FRART-PC study), 3) among the patients with metastatic PC (FRAM-PC study), 4) the association of baseline frailty and quality of life (FRAQ-PC study), and 5) the association of baseline frailty and postoperative pain (FRAP study).
In the RCC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) in the patients with radical or partial nephrectomy (FRARN study), 2) between in the mRCC patients with molecular targeted therapy and/or immunotherapy(FRARMT study), and 4) the association of baseline frailty and quality of life (FRAQ-RCC). Also, we planned to estimate the gap between chronological and biological age using frailty (FRAGE-GAP study).
英語
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-UC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
In the PC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments (FRAPC study), the effect of frailty on safety and oncological outcomes 2) between the radical prostatectomy and radiation therapy in patients with localized prostate cancer (FRART-PC study), 3) among the patients with metastatic PC (FRAM-PC study), 4) the association of baseline frailty and quality of life (FRAQ-PC study), and 5) the association of baseline frailty and postoperative pain (FRAP study).
In the RCC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) in the patients with radical or partial nephrectomy (FRARN study), 2) between in the mRCC patients with molecular targeted therapy and/or immunotherapy(FRARMT study), and 4) the association of baseline frailty and quality of life (FRAQ-RCC). Also, we planned to estimate the gap between chronological and biological age using frailty (FRAGE-GAP study).
2020 | 年 | 03 | 月 | 19 | 日 |
2023 | 年 | 03 | 月 | 21 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/icdr/ctr_view.cgi?recptno=R000045480
英語
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000045480